Back
EHRA 2024 Premium Access

Effects of age, sex, cardiovascular comorbidities, and kidney function on outcomes with oral anticoagulation therapy in patients with device-detected atrial fibrillation. The NOAH-AFNET 6 trial.

Session: Late-Breaking Science: devices
Topic: Oral Anticoagulation
Speaker: Doctor J. Nikorowitsch (Hamburg, DE)
Event: EHRA 2024

Congress Presentation

About the speaker

Doctor Julius Nikorowitsch

University Heart and Vascular Centre Hamburg (UHZ), Hamburg (Germany)
1 presentation
0 follower

9 more presentations in this session

Clinical benefits of the Closed Loop Stimulation in Sinus Node Disease

Speaker: Doctor E. Pisano (Lecce, IT)

Access
Slides
Video
Thumbnail

Clinical benefits of the Closed Loop Stimulation in Sinus Node Disease - discussion

Speaker: Doctor N. Varma (Cleveland, US)

Access
Slides
Video
Thumbnail

Effects of age, sex, cardiovascular comorbidities, and kidney function on outcomes with oral anticoagulation therapy in patients with device-detected atrial fibrillation. The NOAH-AFNET 6 trial. - discussion

Speaker: Doctor S. Al-Khatib (Durham, US)

Access
Slides
Video
Thumbnail

Risk of stroke or systemic embolism according to baseline frequency and duration of subclinical atrial fibrillation: Insights from the ARTESiA trial

Speaker: Doctor W. McIntyre (Hamilton, CA)

Access
Slides
Video
Thumbnail

Risk of stroke or systemic embolism according to baseline frequency and duration of subclinical atrial fibrillation: Insights from the ARTESiA trial - discussion

Speaker: Associate Professor T. Potpara (Belgrade, RS)

Access
Slides
Video
Thumbnail

Access the full session

Late-Breaking Science: devices

Speakers: Doctor J. Nikorowitsch, Doctor E. Pisano, Doctor N. Varma, Doctor S. Al-Khatib, Doctor W. McIntyre...
Access
Video
Thumbnail

About the event

Image

EHRA 2024

7 April - 9 April 2024

Sessions Presentations

Congress
logo Image

ESC 365 is supported by

logo Novo Nordisk
logo Bristol Myers Squibb